Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulforaphane for Therapeutic Prevention of Melanoma
NCT07040280Phase 2Recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Feb 2026
- Primary completion
- Mar 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in melanoma comparing Arm A (sulforaphane) with Arm B (placebo) (2 arms). Primary endpoint: Change in total area of atypical and common pigmented nevocellular nevi on the posterior trunk at 12 months. Started Feb 2026; status: recruiting.
02
Drugs
sulforaphane
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07040280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040280.